ENTA Shares Outstanding History
Below is a table of the ENTA shares outstanding history going back to 3/21/2013:

Date ENTA Shares Outstanding
3/21/201316.84M
5/10/201317.82M
8/9/201317.91M
12/16/201317.96M
2/10/201418.36M
5/9/201418.54M
8/8/201418.58M
12/1/201418.60M
1/30/201518.68M
4/30/201518.69M
7/31/201518.71M
11/30/201518.80M
1/31/201618.93M
5/1/201618.96M
8/1/201619.04M
12/1/201619.04M
12/27/201619.04M
2/1/201719.04M
5/1/201719.08M
8/1/201719.09M
12/1/201719.13M
2/1/201819.16M
5/1/201819.27M
8/1/201819.38M
11/1/201819.42M
1/31/201919.44M
4/28/201919.67M
7/30/201919.68M
7/26/201932.71M
11/1/201919.73M
1/31/202019.92M
4/30/202020.00M
7/30/202020.07M
11/1/202020.08M
1/31/202120.17M
4/26/202120.20M
7/29/202120.21M
11/1/202120.32M
1/31/202220.53M
4/27/202220.71M
8/2/202220.72M
11/1/202220.80M

Also see: ENTA Market Cap History
ENTA YTD Return
ENTA Historical Shares Outstanding:
+2.22% CAGR
ENTA Historical Shares Outstanding: +2.22% CAGR

Mouse over chart for data details
3/21/2013 ...11/1/2022
Enanta Pharmaceuticals is a biotechnology company that engaged in the discovery and development of small molecule drugs for the treatment of viral infections. Co.'s primary wholly-owned research and development programs are in virology, namely respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, hepatitis B virus and human metapneumovirus. Co.'s out-licensed products include two protease inhibitors, which are developed through Co.'s Collaborative Development and License Agreement with AbbVie have been clinically tested, manufactured, and commercialized by AbbVie as part of its combination regimens for hepatitis C virus. We show 42 historical shares outstanding datapoints in our coverage of ENTA's shares outstanding history.

Understanding the changing numbers of ENTA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ENTA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ENTA by allowing them to research ENTA shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree ENTA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Enanta Pharmaceuticals (ENTA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

ENVB Shares Outstanding History
ENZ Shares Outstanding History
EOLS Shares Outstanding History
EPZM Shares Outstanding History
EQ Shares Outstanding History
ERAS Shares Outstanding History
ERNA Shares Outstanding History
ESPR Shares Outstanding History
ESRX Shares Outstanding History
ETNB Shares Outstanding History
More Healthcare companies »

 

ENTA Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2023, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.